GSK has won FDA approval for Jideytro, a drug at the heart of its $10.6 billion acquisition of Nuvalent earlier this year – as a treatment for a form of lung cancer. The drug was effective in patients with ROS1 mutations, as well as those whose cancer had spread to the brain. "The responses observed in ARROS-1, including in heavily pre-treated patients, represent meaningful progress for people living with this disease." GSK's lung cancer pathfinder productJideytro is GSK's first lung cancer therapy, and one of three for the disease added by the UK-headquartered pharma group through the takeover of Nuvalent, which was announced in June and closed last week. Meanwhile, GSK is also developing another lung cancer candidate – B7-H3-targeted antibody-drug conjugate (ADC) risvutatug rezetecan (ris-rez) – which is licensed from Hansoh Pharma and recently had a positive phase 3 readout in relapsed small-cell lung cancer (SCLC).